Steven Fletcher

12PUBLICATIONS
4CO-AUTHORS
Biologically active moleculesProteins and peptidesMolecular medicineMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 27, 2026
Lead optimization of 5jc21 (CG13250), a quinolin-2(1H)-one-based inhibitor of the BRD4 member of the bromodomain and extraterminal (BET) family of proteins.

|Feb 02, 2026
Protein structural dynamics in covalent drug design: insights from irreversible and reversible covalent inhibitors.

Ruchira Basu, Steven Fletcher

|Jan 14, 2026
First-in-Class Potent, Dual HDAC6/Proteasome Inhibitors Lacking a Hydroxamic Acid Motif: Discovery of Novel Anti-Multiple Myeloma Agents.

Alexandria M Chan, Brandon D Lowe, Andrea L Cottingham

|May 19, 2025
Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation.

Sarah Pogash, Steven Fletcher

|May 15, 2025
Augmenting the Anti-Leukemic Activity of the BCL-2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL-2/HDAC1 and Dual BCL-2/HDAC6 Inhibitors.

Alexandria M Chan, Christian Eberly, Brandon Drennen

|Nov 29, 2023
Tetrazole and acylsulfonamide bioisosteric replacements of the carboxylic acid in a dual MCL-1/BCL-xL inhibitor are tolerated.

Lijia Chen, Brandon Lowe, Steven Fletcher

Pageof 2

Frequent Collaborators

1 joint publications

Alexandria M Chan

1 joint publications

Asaminew H Aytenfisu

1 joint publications

Jace W Jones

1 joint publications

Ryan M Pearson